Systems Medicine for Lung Diseases: Phenotypes and Precision Medicine in Cancer, Infection, and Allergy

  • Bernd SchmeckEmail author
  • Wilhelm BertramsEmail author
  • Xin Lai
  • Julio Vera
Part of the Methods in Molecular Biology book series (MIMB, volume 1386)


Lung diseases cause an enormous socioeconomic burden. Four of them are among the ten most important causes of deaths worldwide: Pneumonia has the highest death toll of all infectious diseases, lung cancer kills the most people of all malignant proliferative disorders, chronic obstructive pulmonary disease (COPD) ranks third in mortality among the chronic noncommunicable diseases, and tuberculosis is still one of the most important chronic infectious diseases. Despite all efforts, for example, by the World Health Organization and clinical and experimental researchers, these diseases are still highly prevalent and harmful. This is in part due to the specific organization of tissue homeostasis, architecture, and immunity of the lung. Recently, several consortia have formed and aim to bring together clinical and molecular data from big cohorts of patients with lung diseases with novel experimental setups, biostatistics, bioinformatics, and mathematical modeling. This “systems medicine” concept will help to match the different disease modalities with adequate therapeutic and possibly preventive strategies for individual patients in the sense of precision medicine.

Key words

Asthma Allergy Infection Pneumonia Mycobacteria Immunology Transplantation Model organisms Gas exchange Personalized medicine 

1 Introduction

Among the ten most common causes of death worldwide, there are four pulmonary diseases, killing 9.5 million people per year (Fig. 1 ) [1]. In addition, pneumonia, COPD, tuberculosis, and lung cancer are also among the ten most common causes of disability-adjusted life years (DALYs) lost worldwide. Pneumonia alone is the single most important cause of DALYs lost, more important than HIV/AIDS, ischemic heart disease, cerebrovascular disease, or diarrhea [2]. The total cost of lung diseases in the European Union amounts to more than €380 billion annually. In addition to the abovementioned diseases, asthma alone causes costs of over €72 billion, consisting of €19.5 billion for direct medical costs, €14.4 billion for lost productivity (work absence, early retirement, etc.), and €38.3 billion for monetized value of DALYs. Lung cancer causes the greatest socioeconomical loss from disability and premature mortality. Because of late diagnosis and limited treatment options, most treatment costs are concentrated within the year of the diagnosis. Therefore, the total annual costs per case are calculated as €364,000 for lung cancer [2].
Fig. 1

Frequent lung diseases and related systems medicine consortia. Depicted are the four lung diseases with the highest mortality worldwide, including death worldwide 2011, disability-adjusted life-years (DALYs) lost 2008, aggregated annual total (direct and indirect) costs and the value of DALYs lost for EU countries 2011, and related systems medicine projects according to internet and database research [1, 2]

The lung and airways provide many unique features in terms of anatomy, physiology, and immunology. This paves the way for manifold pathologies and presents challenges for pulmonary clinicians and researchers. The lung is the body’s largest organ, but contains about four liters of air and only about half a liter of tissue and the same amount of blood [3]. Therefore, the organ tissue has to be organized in a sophisticated and delicate way. The main function of the lung is the exchange of two gases, O2 and CO2, between the air that we breathe and the bloodstream. Three main processes are involved in this: ventilation of air along the bronchial tree, passive diffusion of gases, and perfusion of blood through the alveolar capillaries [4]. These processes are tightly regulated, and not every part of the lung is equally ventilated and perfused. Every day, about 10,000 l of air—containing pollutants, allergens, pathogens, etc.—is ventilated through the about 23 generations of dichotomically dividing airways and over a lung surface of about 130 m2 that is condensed mainly in over 300 million alveoli. The capillary surface has about the same size. Diffusion of oxygen critically depends on a short diffusion distance over the air–blood barrier [3]. In healthy lungs, the mean thickness of this tissue barrier is about 0.6 μm, consisting of very thin parts of alveolar epithelial type I cells and capillary endothelial cells sharing one single layer of basement membrane [5]. This delicate architecture is only possible due to the surfactant layer that lines the alveolar surface, reduces its surface tension, and is released by alveolar epithelial type II cells.

2 Clinical Challenges

2.1 Acute Infection: Pneumonia

Community-acquired pneumonia is a high incidence disease which results in more hospital admissions per year in some industrialized countries than myocardial infarction [6, 7]. It has the highest mortality rate worldwide of all infectious diseases. Its lethality ranges from 1 % in outpatient settings to 35 % in high-risk patients [8]. UNICEF (the United Nations Children’s Fund) data suggest that pneumonia kills more children under the age of 5 than malaria, AIDS, and measles together [9]. Notorious problems are emerging new pathogens that may combine a high mortality with an easy transmission, e.g., the SARS and MERS coronaviruses or certain pandemic influenza strains [10]. Severe pneumonia can lead to sepsis and septic shock requiring intensive care treatment with artificial organ support, causing extremely high costs [11]. Recently, it has been observed that pneumonia patients face an increased death risk for several months after the acute infection [8].

2.2 Chronic Inflammation: Asthma

Asthma is classically defined as an inflammatory chronic airway disease characterized by reversible airway obstruction and airway hyperresponsiveness [12]. This disease affects 200–300 million people worldwide, and its prevalence has been increasing over the last decades [13]. Up to 10 % of asthmatics are considered as severe cases. Typically, the inflammation in asthma is described to be allergic, eosinophilic, IgE dependent, and Th2 driven [14]. Therefore, therapy besides bronchodilation targets mainly this eosinophilic inflammation, either unspecific with topical or systemic glucocorticoids, with antileukotriene drugs, or with “biological therapies” specifically addressing IgE, or probably in the future IL-13, IL-5, and others [15]. However, sufficient control of asthma symptoms is impossible in many patients, in part due to more than 50 % of asthma patients that do not show a persistent eosinophilic inflammation [16], and this seriously challenges the classical pathophysiological concepts. Systems-based approaches can help to stratify patients to their phenotypes and respective available therapies and to identify new targets for the treatment of patients that are unresponsive to existing drugs [17].

2.3 Chronic Inflammation: COPD

Chronic obstructive pulmonary disease (COPD) is the third most common noncommunicable disease with a very high prevalence worldwide. It causes significant disability, mortality, and health-care costs, e.g., for lifelong medication, lung transplantation, or mechanical ventilation. The most common causes for the development of COPD are long-term exposure to primary or secondary tobacco smoke, combustion of biomass, e.g., by open-fire cooking in developing countries, or genetic predisposition. Increasing evidence indicates that COPD is rather a syndrome than a solitary disease. The pathophysiological hallmarks are (1) chronic, cortisone-insensitive inflammation which causes mucus hypersecretion and fixed bronchoconstriction and remodeling as well as (2) irreversible tissue destruction in terms of bronchiectasis and emphysema [18]. They result in respiratory and ventilatory failure. An aggravating aspect is the vicious circle of impaired innate immunity, chronic bacterial colonization, and recurrent viral or bacterial infections called exacerbations and often resulting in hospitalization [19]. Besides substance avoidance and exercise training, COPD symptoms are typically treated by long-acting airway dilators on a lifelong basis. The underlying pathophysiology of chronic airway inflammation can be targeted by either topic or systemic glucocorticoids or phosphodiesterase inhibitors. However, these treatments are hampered by side effects and low effectivity. Increasing numbers of patients with severe ventilatory insufficiency receive lifelong mechanical ventilation, which is expensive and requires special infrastructure. On the other hand, the chances of COPD patients to receive lung transplantation are decreasing due to high risk of, e.g., cardiovascular or metabolic comorbidities .

2.4 Pulmonary Hypertension

Pulmonary hypertension is a disease of the lung vasculature. Hallmarks are a deregulated proliferation of different vascular cell types and a progressive obliteration of vessels [20]. This often results in an increased pulmonary vascular resistance, increased right heart afterload, and cor pulmonale. Pulmonary hypertension is caused by a combination of genetic and environmental factors. It occurs in a variety of clinical situations and heterogeneous phenotypes. Several histological patterns of abnormalities have been described. Despite significant progress that has been made in understanding the pathogenesis and the development of new methods for delaying the progression of the disease, there is still no cure for it [21].

2.5 Cancer

Lung cancer displays the highest neoplasia-related mortality in man. Over the last years, its mortality is also increasing in women. Cure rates and prognosis are generally poor due to late diagnosis. Therefore, a major focus lies on screening and early diagnosis [22]. Another important challenge is the correct molecular diagnosis for a targeted therapy. Up to now, lung cancer is subdivided in so-called small cell lung cancer (SCLC, of neuroendocrine origin) and non-small cell lung cancer (NSCLC, e.g., squamous cell cancer, adenocarcinoma). Recently, certain mutations have been found to be predictive for the sensitivity to new targeted therapies [23]. Therefore, cancer might be the first entity of lung diseases matching the concept of precision medicine [24]. Lung cancer is mainly caused by exposure to primary or secondary tobacco smoke, biomass combustion, or naturally occurring radon [25].

3 Methodological Challenges: “The Mouse Trap”

The basic aim of systems medicine is to model human pathophysiology and disease to advance our understanding and to improve clinical diagnosis and treatment. Therefore, it is a logical and straightforward strategy to establish big and well-characterized patient cohorts to collect as many clinical and molecular data as possible—and suitable—as a solid base for this modeling process. However, certain processes or features cannot be observed or tested neither in healthy volunteers nor in patients. This includes the early origins of disease, e.g., environmental influence on asthma predisposition that may be epigenetically transferred from mother to child, the initial pathophysiological events in the alveolus during development of an influenza virus-induced pneumonia, and many more. In part, these problems can be resolved by the use of cell culture or tissue culture models [26]. However, some aspects can only be addressed in a living organism. In the past, for academic experimental research as well as for drug candidate studies for subsequent human trials, mice have been used to model human diseases because of the practical convenience (easy handling and low costs), the possibility to generate transgenic or gene knockout animals, and the availability of molecular and immunological tools [27]. However, certain caveats have to be kept in mind: Firstly, some of the lung diseases, e.g., asthma, are unique to humans and do not occur naturally in mice. Secondly, the anatomy and (patho-)physiology may differ significantly between mice and humans. Besides the obvious size difference—the human lung has a volume of 5 l, and the murine lung has a volume of 1 ml—there are also significant anatomical and physiological differences. For instance, the human airways have 23 generations, and the murine has only 13–16, the human airway division is dichotomic, and the murine airway division is monopod; mice do not have respiratory bronchioli, and the cellular composition and vascularization of the lung are different for both species [5, 27, 28]. Moreover, mice strains differ in their likelihood to react to stressors with certain pathophysiological events. In addition, there is increasing evidence that the immune systems of mice and men differ significantly. For trauma, burns, and endotoxemia, Seok and co-workers compared gene response patterns between human subjects and corresponding mouse models: They found that these stressors resulted in highly similar patterns in humans, whereas the responses in corresponding mouse models showed only poor correlations with human conditions and also among each other [29]. Accordingly, there are several examples where the reliance on animal models misguided the pathophysiological understanding [28], led to unsuccessful clinical trials [29], or even resulted in disastrous outcomes of clinical studies [30]. This may be in part due to differences in the molecular repertoire of immune cells in mice and humans: For example, the inherent versatility of macrophages harbors the potential for a plethora of different activation subtypes [31]. Inappropriate polarization can be detrimental to the host, as macrophages can potentiate an inapt immune response and thus aggravate a pathological condition: In rodents, alveolar macrophages have been found to play an important role for the development of airway hyperresponsiveness in allergic animals [32, 33]. In mice, solid markers for macrophage polarization are established, as is exemplified by the well-described induction of NOS2 in M1(IFNγ) and of ArgI in M2 (IL-4) macrophages. Corresponding functional markers in the human system are yet to be found, and there are notable differences between human and murine macrophage activation patterns on the transcriptional level [34]. Accordingly, a comparative study of M2 (IL-4) polarization in mouse and man shows very limited interspecies consistency, as only transglutaminase 2 (TGM2) was found to be a functional marker shared by both [35].

4 Case Studies

4.1 Modeling Lung Infection

The most frequent cause of community-acquired pneumonia is pneumococcal infection. Smith and co-workers established a mathematical model to predict the outcome of pneumococcal pneumonia with the two possible states (1) bacterial clearance, or (2) sustained bacterial growth [36]. The model is based on data of pulmonary bacterial replication from a mouse model of pneumococcal pneumonia. Using ordinary differential equations (ODEs), it describes three lines of barrier defense: First, the initial alveolar macrophage response mounts a fast but weak defense and is described by only one equation for the bacterial population. Second, the early recruitment of neutrophils consist of cytokine release by different populations of alveolar macrophages and epithelial cells, the influx of neutrophils, neutrophil apoptosis, and debris removal by alveolar macrophages. Third, a subsequent recruitment of monocyte-derived macrophages has been included that contributes to bacterial killing. This model provides some interesting insights and sufficient accuracy for certain questions, although it is of moderate complexity and based on limited experimental data. Some more data from previously published mouse studies have been included in another effort to model pneumococcal pneumonia: Bacterial numbers in the lung and the blood and also neutrophil levels from infection experiments with four differently susceptible mouse strains [37] have been used to calibrate this ODE model. It consists of four equations describing the time evolution of the number of pathogens in the lung and in the blood, damaged lung epithelial cells, and total activated phagocytes. The model has been validated on other published data sets, and its predictions are consistent with most experimental observations. However, no study so far has modeled pneumonia dynamics in patients. Therefore, a new consortium (“Medical Systems Biology of Pulmonary Barrier Failure in Community Acquired Pneumonia; e:Med CAPSYS” [38]) aims at multiscale modeling of pulmonary barrier failure in bacterial pneumonia based on comprehensive physiological, proteomic, and transcriptomic data sets from clinical cohorts, complex mouse models, and human cell culture models (Fig. 1). It will include three cohorts: 10,000 well-phenotyped pneumonia patients of the CAPNETZ study (clinical, biochemical, and genetic data) [39], more than 1000 patients with uncomplicated or severe pneumonia or pneumogenic sepsis (several visits, data from genotyping, expression profiling, and proteomics), and a newly recruited deep-phenotyping cohort of about 100 patients that will undergo, e.g., bronchoscopy for microbiome and exosome analysis.

Several mathematical models have been developed to study and understand host immune response mechanisms in pulmonary Mycobacterium tuberculosis (Mtb) infection. Marino and Kirschner [40] used a two compartment model to investigate the human immune response to Mtb in the lung. By performing bifurcation analysis of the model, the authors identified key processes of cellular activation and priming that occur between the lung and the nearest draining lymph node that have the potential to determine different outcomes of the Mtb infection. To identify control mechanisms of granuloma formation during Mtb infection in the lung, Segovia-Juarez et al. [41] built a complex agent-based model which accounts for interactions between Mtb, immune effectors such as chemokines and cytokines, and immune cells like macrophages, CD4+, and CD8+ T cells. With the help of the model, the authors identified several issues that are crucial for granuloma formation during the course of Mtb infection, including efficiency of chemokine diffusion, prevention of macrophage overcrowding within the granuloma, arrival time, location, and number of T cells within the granuloma, as well as overall host ability to activate macrophages. To investigate the contribution of CD8+ T cells to control Mtb infection, Sud et al. [42] built an ODE model of the immune response to Mtb in the lung. Using the model, the authors examined the importance of CD8+ T cells in the control of the infection and determined putative minimum T cell levels providing effective protection following vaccination. A model of differential equations was also developed to investigate the different roles played by alternatively activated macrophages (AAM) versus classically activated macrophages (CAM) in the early stages of Mtb infection in the lung. The model described the interactions among cells, bacteria, and cytokines involved in the activation of AAM and CAM and was a useful tool to analyze strategies for reducing the switching time (i.e., when CAM become more dominant than AAM), which ensures an adequate immune response to the pathogen [43]. Similarly, Kirschner’s group built two ODE models to investigate the function of macrophage (CAM)-activating cytokines (i.e., TNFα and IFNγ) in Mtb infection. One model was used to test the ability of macrophages to kill Mtb under different scenarios, in which the macrophage activation is characterized by the timing of IFNγ and TNFα signaling relative to the infection [44]. The model simulations unraveled a preferred host strategy for mycobacterial control that is implemented via the direct entry of macrophages into a granuloma site from lung vascular sources. The other model was used to predict the contribution of multiple TNFα activities to the control of Mtb infection within the granuloma, with the assumption that macrophage activation is a key effector mechanism for controlling bacterial growth in the lung. The simulation results suggested that bacterial numbers are a strong contributing factor to granuloma structure with TNF, and TNF-dependent apoptosis can reduce inflammation at the cost of impairing mycobacterial clearance [45].

One of the fundamental challenges in the control of pulmonary Mtb infection is to understand molecular mechanisms involved in the onset of latency and/or reactivation of Mtb after the initial infection. Magombedze and Mulder [46] built a mathematical model to simulate all possible Mtb latency occurrence scenarios in the lung based on the profile of differentially expressed genes. Their ODE model was used to simulate observed gene expression changes in in vitro latency models which allow for illustrating all possible latency/dormancy occurrence scenarios and latency reactivation. In a subsequent study, the same author used a systems biology approach combing both bioinformatics and mathematical modeling to identify potential drug target genes in the Mtb latency program. Boolean modeling of the data-driven regulatory network related to mycobacterial latency in the lung revealed a bistable switch between latent and actively replicating phases of Mtb [46].

4.2 Modeling Asthma

Multiscale models of the lung have been developed and applied to gain a better understanding of asthma in several aspects. These models incorporate and couple multiple spatial scales (molecules, cells, tissues, and the lung) underlying airway hyperresponsiveness to simulate the complex physiological response to, e.g., allergens in asthma. Venegas et al. carried out a study that probed the scale of ventilation heterogeneity in asthmatic subjects using positron emission tomography imaging and that modeled complex interdependent behavior in the lung [47]. The authors found that ventilation is not uniform within bronchoconstricted regions, and within the ventilation defects themselves, there is considerable ventilation heterogeneity. Brook et al. developed an axisymmetric two-layer model of an airway wall to represent both lung slices and an intact airway in vivo, which resolves connective tissue and muscle cell properties within a composite muscle layer [48]. The model predicted that different types of airway remodeling in asthma lead to significantly different contractile responses and stress environments. For better understanding of airway hyperresponsiveness in asthmatic airways, a multiscale model of partial and ordinary differential equations was developed, which linked regulatory processes occurring at molecular and cellular level (Ca2+ and crossbridge dynamics) with physiological phenomena occurring at the organ level (lung deformation) [49, 50]. Chernyavsky et al. developed a mathematical model that qualitatively describes the growth dynamics of airway smooth muscle cells (ASM) over short and long terms in the normal and inflammatory environments typically observed in asthma [51]. This model allowed possible ASM accumulation scenarios to be explored and suggested possible new targets for diagnosis and prevention of ASM remodeling in asthma.

Recently, new consortia have started to apply systems biology strategies to asthma in a clinical context: Within the Innovative Medicines Initiative, a European project aims at a personalized management approach for patients with severe asthma (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome Consortium; U-BIOPRED ) [52]. It involves scientists from universities, research institutes, the pharmaceutical industry, and small companies and plans to define phenotypes with respect to therapeutic efficacy by integrating -omics data from invasively and noninvasively obtained patient material and modeling of the underlying pathologies [53]. Another project aims to develop validated models that predict disease progression and response to treatment in asthma and COPD by integrating expertise in physiology, radiology, image analysis, bioengineering, data harmonization, security and ethics, computational modeling, and systems biology (Airway Disease Predicting Outcomes through Patient Specific Computational Modeling Consortium; AirPROM ) [54]. This project is funded by the European Union 7th Framework Programme. Recently, the German Center for Lung Research (DZL) has established a systems biology platform [55] to integrate patient data from its cohorts for childhood wheezing and severe asthma in adults with experimental models by means of multiscale modeling.

4.3 Modeling Other Lung Diseases

To investigate airway disease resulting from inflammation and fibrosis following particulate exposure, Brown et al. used an agent-based model, which focuses on a limited number of relevant interactions, specifically those among macrophages, fibroblasts, pro-inflammatory (TNFα) and anti-inflammatory cytokines (TGFβ1), collagen deposition, and tissue damage [56]. The model predicted three distinct states of inflammation whose developments depend primarily on the degree and duration of particulate exposure. The predictions were consistent with in vivo experimental observations obtained after exposing mice lung tissue to particulate matter.

A mathematical model composed of partial differential equations that describe the interactions among immune cells and cytokines related to sarcoidosis in the lung was built by Hao et al. [57]. The model was calibrated and validated using clinical data on cytokine levels in healthy and diseased lung tissues and further used to explore the effect of potential treatments (such as anti-TNFα, anti-IL-12, anti-IFNγ, and TGFβ enhancement) that may reduce the disease activity through decreasing the size of sarcoid granulomas. Taken together, the constructed model is a step toward a more comprehensive study of sarcoidosis and its treatment.

Many end-stage respiratory diseases require lung transplantation as a last resort. However, with 27 % overall 10-year survival, this procedure shows the poorest long-term survival of all solid organ transplantations [58]. The main reason for this is the development of chronic lung allograft dysfunction (CLAD) by over 50 % of all lung transplant recipients within 5 years. Therefore, 14 lung transplantation centers teamed up to build a computational model to estimate the personal recipient risk to develop CLAD within 3 years after the transplantation (systems biology of CLAD, SysCLAD). They will analyze clinical, environmental, and immunological data, the microbiome and different -omics data both from donors and recipients [59].

One question that is still unsolved in lung cancer is how circulating tumor cells can develop at the primary site and traverse the circulatory systems. Having in mind the difficulties to generate suitable in vivo data to elucidate this question, mathematical modeling under the systems biology paradigm seems to be a good methodological option. In line with this, Kuhn’s group used a Markov chain Monte Carlo model that describes cancer progression to identify and quantify the multidirectional pathways and timescales associated with metastatic spread from primary lung cancer [60, 61]. In contrast to the traditional view of cancer metastasis as a unidirectional process starting at the primary site and spreading to distant sites as time progresses, the authors quantified three types of multidirectional mechanisms of cancer progression based on large autopsy data sets: (1) self-seeding of the primary tumor, (2) reseeding of the primary tumor from a metastatic site, and (3) reseeding of metastatic tumors [61]. By simulating the model, the authors showed that for lung cancer, the main spreaders (i.e., the distant site that has higher probability of transmitting than keeping circulating tumor cells from the primary site) are the adrenal gland and kidney, whereas the main sponges (i.e., the distant site that has lower probability of transmitting than keeping circulating tumor cells from the primary site) are regional lymph nodes, the liver, and bone.

4.4 Modeling Gas Exchange within the Lung and the Dynamics of Inhaled Pharmaceuticals for Lung Diseases

Mathematical models have been utilized not only for a system-level understanding of the whole respiratory system but also for a detailed understanding of several functions that contribute to gas exchange within the lung (reviewed by Ben-Tal and Tawhai [62]). Particularly, two studies have been carried out to investigate the effect of ventilation/perfusion mismatch on hepatopulmonary syndrome and lung inflammation, respectively. Chakraborty et al. developed a differential equation model of pulmonary oxygen uptake by considering three disparate scales, namely, micro (red blood cell), meso (capillary and alveolus), and macro (lung) [63]. The authors used the model to quantify the oxygen uptake abnormalities in patients with hepatopulmonary syndrome as a result of functional intrapulmonary right to left shunting of pulmonary blood flow, as well as spatial heterogeneity of ventilation/perfusion mismatch in the lung. Furthermore, the quantified pulmonary gas exchange abnormalities in the patients were used for stratifying them into two categories—those who are oxygen responsive and those who are oxygen nonresponsive with intractable hypoxemia. Reynolds et al. [64] developed a multi-compartment model of ODEs for gas exchange with focus on inflammation in acute lung injury. Using the model, the authors explored effects of inflammation on ventilation/perfusion distribution and the resulting pulmonary venous partial pressure oxygen level during systemic inflammatory stresses.

In the last years, a number of compartment-based pharmacokinetic (PK) models accounting for the kinetics of inhaled pharmaceuticals have been published. For instance, Sturm [65] developed a stochastic model describing mucociliary clearance in cystic fibrosis patients and its development with progressing course of the disease. The model showed that patients with cystic fibrosis have a higher risk of inhaled particle accumulation and related particle overload in specific lung compartments than healthy subjects. Markovetz et al. built a more complex model to describe the mucociliary clearance and absorption of aerosolized radiolabeled particles and small molecular probes from human subjects with and without cystic fibrosis [66]. This model captured the mucociliary clearance and liquid dynamics of the hyperabsorptive state in cystic fibrosis airways and the mitigation of that state by hypertonic saline treatment.

5 Perspectives

Despite all clinical and scientific efforts so far, lung diseases cause an enormous suffering and death toll from patients and socioeconomical costs for our societies and health-care systems, especially in the fields of infection, malignancies, chronic noncommunicable diseases, and allergy. This may be in part due to complicated, even prenatal, timelines, and heterogeneous clinical phenotypes. On the other hand, new scientific insights, e.g., in the role of the microbiome and noncoding RNA, and new technological developments, e.g., the new sequencing technologies, may help us to improve our clinical performance in future. But these tremendous amounts of clinical and molecular data require a new way of organizational, technological, and intellectual cooperation between many clinical, experimental, and theoretical disciplines, called “systems medicine.” Many questions remain to be answered: What type and amount of clinical data do we need and can we afford to collect and analyze? What will be the role of animal models, human tissue models, complex cell culture models, or even artificial organs on a chip? How can we bring all these complex and multilevel data together by means of mathematics and computer science? Improving clinical practice in respiratory medicine will require enthusiasm and hard work from all participating physicians and scientists, as well as sustained support by our governments, funding agencies, and all stakeholders of our health-care systems.



We thank many collaborators for fruitful discussion, especially Annalisa Marsico, Brian Caffrey, and Martin Vingron. Part of this work has been funded by BMBF (e:bio miRSys, FKZ 0316175B, and e:Med CAPSYS, FKZ 01X1304E) to B.S. and J.V., and DFG (SFB/TR-84) and HMWK (LOEWE Medical RNomics—FKZ 519/03/00.001-(0003)) to B.S. We would like to apologize to all colleagues whose excellent contributions to the field could not be included in this text due to space constraints.


  1. 1.
  2. 2.
    Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B (2013) The European lung white book. European Respiratory Society, SheffieldGoogle Scholar
  3. 3.
    Murray JF (2010) The structure and function of the lung. Int J Tubercul Lung Dis 14:391–396Google Scholar
  4. 4.
    Wagner PD (2015) The physiological basis of pulmonary gas exchange: implications for clinical interpretation of arterial blood gases. Eur Respir J 45:227–243CrossRefPubMedGoogle Scholar
  5. 5.
    Weibel ER (2013) It takes more than cells to make a good lung. Am J Respir Crit Care Med 187:342–346CrossRefPubMedGoogle Scholar
  6. 6.
    Angus DC, Marrie TJ, Obrosky DS et al (2002) Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 166:717–723CrossRefPubMedGoogle Scholar
  7. 7.
    Ewig S, Birkner N, Strauss R et al (2009) New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 64:1062–1069PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Restrepo MI, Faverio P, Anzueto A (2013) Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 26:151–158PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    UNICEF/WHO (2006) Pneumonia, the forgotten killer of children.
  10. 10.
    Horby PW, Pfeiffer D, Oshitani H (2013) Prospects for emerging infections in East and Southeast Asia 10 years after severe acute respiratory syndrome. Emerg Infect Dis 19:853–860PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Angus DC, Van Der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851CrossRefPubMedGoogle Scholar
  12. 12.
    Busse WW, Lemanske RF Jr (2001) Asthma. N Engl J Med 344:350–362CrossRefPubMedGoogle Scholar
  13. 13.
    Eder W, Ege MJ, Von Mutius E (2006) The asthma epidemic. N Engl J Med 355:2226–2235CrossRefPubMedGoogle Scholar
  14. 14.
    Accordini S, Corsico AG, Braggion M et al (2013) The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 160:93–101CrossRefPubMedGoogle Scholar
  15. 15.
    Haldar P, Pavord ID, Shaw DE et al (2008) Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178:218–224PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183–192CrossRefPubMedGoogle Scholar
  17. 17.
    Gonem S, Desai D, Siddiqui S et al (2011) Evidence for phenotype-driven treatment in asthmatic patients. Curr Opin Allergy Clin Immunol 11:381–385CrossRefPubMedGoogle Scholar
  18. 18.
    Mcdonough JE, Yuan R, Suzuki M et al (2011) Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365:1567–1575PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Sethi S, Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355–2365CrossRefPubMedGoogle Scholar
  20. 20.
    Huang JB, Liang J, Zhao XF et al (2013) Epigenetics: novel mechanism of pulmonary hypertension. Lung 191:601–610CrossRefPubMedGoogle Scholar
  21. 21.
    Colvin KL, Yeager ME (2015) Proteomics of pulmonary hypertension: could personalized profiles lead to personalized medicine? Proteomics Clin Appl 9:111–120CrossRefPubMedGoogle Scholar
  22. 22.
    Prosch H, Schaefer-Prokop C (2014) Screening for lung cancer. Curr Opin Oncol 26:131–137CrossRefPubMedGoogle Scholar
  23. 23.
    Reck M, Heigener DF, Mok T et al (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382:709–719CrossRefPubMedGoogle Scholar
  24. 24.
    Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372:793–795CrossRefPubMedGoogle Scholar
  25. 25.
    Kurmi OP, Arya PH, Lam KB et al (2012) Lung cancer risk and solid fuel smoke exposure: a systematic review and meta-analysis. Eur Respir J 40:1228–1237CrossRefPubMedGoogle Scholar
  26. 26.
    Hocke AC, Becher A, Knepper J et al (2013) Emerging human Middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 188:882–886CrossRefPubMedGoogle Scholar
  27. 27.
    Holmes AM, Solari R, Holgate ST (2011) Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov Today 16:659–670CrossRefPubMedGoogle Scholar
  28. 28.
    Mullane K, Williams M (2013) Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85:289–305CrossRefPubMedGoogle Scholar
  29. 29.
    Seok J, Warren HS, Cuenca AG et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110:3507–3512PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Horvath C, Andrews L, Baumann A et al (2012) Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12:740CrossRefPubMedGoogle Scholar
  31. 31.
    Peters-Golden M (2004) The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol 31:3–7CrossRefPubMedGoogle Scholar
  32. 32.
    Zaslona Z, Przybranowski S, Wilke C et al (2014) Resident alveolar macrophages suppress, whereas recruited monocytes promote, allergic lung inflammation in murine models of asthma. J Immunol 193:4245–4253PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Pouliot P, Spahr A, Careau E et al (2008) Alveolar macrophages from allergic lungs are not committed to a pro-allergic response and can reduce airway hyperresponsiveness following ex vivo culture. Clin Exp Allergy 38:529–538CrossRefPubMedGoogle Scholar
  34. 34.
    Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime reports 6:13Google Scholar
  35. 35.
    Martinez FO, Helming L, Milde R et al (2013) Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 121:e57–69CrossRefPubMedGoogle Scholar
  36. 36.
    Smith AM, Mccullers JA, Adler FR (2011) Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. J Theor Biol 276:106–116PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Mochan E, Swigon D, Ermentrout GB et al (2014) A mathematical model of intrahost pneumococcal pneumonia infection dynamics in murine strains. J Theor Biol 353:44–54PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    CAPSyS. Systems Medicine of Community Acquired Pneumonia.
  39. 39.
    Klapdor B, Ewig S, Pletz MW et al (2012) Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J 39:1156–1161CrossRefPubMedGoogle Scholar
  40. 40.
    Marino S, Kirschner DE (2004) The human immune response to Mycobacterium tuberculosis in lung and lymph node. J Theor Biol 227:463–486CrossRefPubMedGoogle Scholar
  41. 41.
    Segovia-Juarez JL, Ganguli S, Kirschner D (2004) Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J Theor Biol 231:357–376CrossRefPubMedGoogle Scholar
  42. 42.
    Sud D, Bigbee C, Flynn JL et al (2006) Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol 176:4296–4314CrossRefPubMedGoogle Scholar
  43. 43.
    Day J, Friedman A, Schlesinger LS (2009) Modeling the immune rheostat of macrophages in the lung in response to infection. Proc Natl Acad Sci U S A 106:11246–11251PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Ray JC, Wang J, Chan J et al (2008) The timing of TNF and IFN-gamma signaling affects macrophage activation strategies during Mycobacterium tuberculosis infection. J Theor Biol 252:24–38PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Ray JC, Flynn JL, Kirschner DE (2009) Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J Immunol 182:3706–3717PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Magombedze G, Mulder N (2013) Understanding TB latency using computational and dynamic modelling procedures. Infect Genet Evol 13:267–283CrossRefPubMedGoogle Scholar
  47. 47.
    Venegas JG, Winkler T, Musch G et al (2005) Self-organized patchiness in asthma as a prelude to catastrophic shifts. Nature 434:777–782CrossRefPubMedGoogle Scholar
  48. 48.
    Brook BS, Peel SE, Hall IP et al (2010) A biomechanical model of agonist-initiated contraction in the asthmatic airway. Respir Physiol Neurobiol 170:44–58CrossRefPubMedGoogle Scholar
  49. 49.
    Politi AZ, Donovan GM, Tawhai MH et al (2010) A multiscale, spatially distributed model of asthmatic airway hyper-responsiveness. J Theor Biol 266:614–624PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Lauzon AM, Bates JH, Donovan G et al (2012) A multi-scale approach to airway hyperresponsiveness: from molecule to organ. Front Physiol 3:191PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Chernyavsky IL, Croisier H, Chapman LC et al (2014) The role of inflammation resolution speed in airway smooth muscle mass accumulation in asthma: insight from a theoretical model. PLoS One 9:e90162PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Bel EH, Sousa A, Fleming L et al (2011) Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 66:910–917CrossRefPubMedGoogle Scholar
  53. 53.
    Auffray C, Adcock IM, Chung KF et al (2010) An integrative systems biology approach to understanding pulmonary diseases. Chest 137:1410–1416CrossRefPubMedGoogle Scholar
  54. 54.
  55. 55.
    iLung—Institute for Lung Research.
  56. 56.
    Brown BN, Price IM, Toapanta FR et al (2011) An agent-based model of inflammation and fibrosis following particulate exposure in the lung. Math Biosci 231:186–196PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Hao WR, Crouser ED, Friedman A (2014) Mathematical model of sarcoidosis. Proc Natl Acad Sci U S A 111:16065–16070PubMedCentralCrossRefPubMedGoogle Scholar
  58. 58.
    Wolfe RA, Roys EC, Merion RM (2010) Trends in organ donation and transplantation in the United States, 1999–2008. Am J Transplant 10:961–972CrossRefPubMedGoogle Scholar
  59. 59.
    Pison C, Magnan A, Botturi K et al (2014) Prediction of chronic lung allograft dysfunction: a systems medicine challenge. Eur Respir J 43:689–693CrossRefPubMedGoogle Scholar
  60. 60.
    Newton PK, Mason J, Bethel K et al (2012) A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS One 7:e34637PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Newton PK, Mason J, Bethel K et al (2013) Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res 73:2760–2769PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Ben-Tal A, Tawhai MH (2013) Integrative approaches for modeling regulation and function of the respiratory system. Wiley Interdiscip Rev Syst Biol Med 5:687–699PubMedCentralCrossRefPubMedGoogle Scholar
  63. 63.
    Chakraborty S, Balakotaiah V, Bidani A (2007) Multiscale model for pulmonary oxygen uptake and its application to quantify hypoxemia in hepatopulmonary syndrome. J Theor Biol 244:190–207CrossRefPubMedGoogle Scholar
  64. 64.
    Reynolds A, Bard Ermentrout G, Clermont G (2010) A mathematical model of pulmonary gas exchange under inflammatory stress. J Theor Biol 264:161–173PubMedCentralCrossRefPubMedGoogle Scholar
  65. 65.
    Sturm R (2012) An advanced stochastic model for mucociliary particle clearance in cystic fibrosis lungs. J Thorac Dis 4:48–57PubMedCentralPubMedGoogle Scholar
  66. 66.
    Markovetz MR, Corcoran TE, Locke LW et al (2014) A physiologically-motivated compartment-based model of the effect of inhaled hypertonic saline on mucociliary clearance and liquid transport in cystic fibrosis. PLoS One 9:e111972PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Pulmonary and Critical Care Medicine, Department of Medicine, University Medical Center MarburgPhilipps-University MarburgMarburgGermany
  2. 2.Systems Biology Platform, Institute for Lung Research/iLung, German Center for Lung Research, Universities of Giessen and Marburg Lung CentrePhilipps-University MarburgMarburgGermany
  3. 3.Laboratory of Systems Tumor Immunology, Department of Dermatology, Faculty of MedicineUniversity of Erlangen-NurnbergErlangenGermany

Personalised recommendations